Despite racial and ethnic minority groups making up nearly half of the United States population, underrepresentation in clinical trials remains a critical challenge. In an effort to improve clinical trial diversity, researchers at The Ohio State University Wexner Medical Center and College of Medicine partnered with The African American Male Wellness Agency, Genentech Inc., and Pfizer, Inc. to engage with almost 450 community members in 25 states and five countries to create solutions to barriers of access, awareness, discrimination and racism, and workforce diversity.
New preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells, were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The meeting is taking place both virtually and at the George R. Brown Convention Center in...
